Kuwabara M, Kodomari Y, Jyo T, Kuraoka T, Mitsuyama T, Kodomari N, Iwamoto K, Miyazawa T, Watanabe T, Morikawa E
Jpn J Antibiot. 1984 Sep;37(9):1685-93.
The clinical effects of cefoxitin (CFX) were studied in 31 cases of respiratory tract infections. The results were as follows: As for the clinical effects, CFX was excellent in 5 cases, good in 13, fair in 8 and poor in 5 out of 31 patients; the efficacy rate was 58.1%. The efficacy rate was 57.1% in bronchopneumonia, 61.1% in pneumonia and 50.0% in acute exacerbation of chronic respiratory tract infections. The efficacy rate was 70.6% in the group of 4 g/day or less and 42.9% in the group of 6 g/day or more. The efficacy rate was 50.0% in 6 cases that had not been responded to other antibiotics previously. As for side effects, skin eruption was observed in only 1 patient. No abnormality was observed in laboratory tests due to CFX. In conclusion, CFX is a useful drug in the treatment of respiratory tract infections.
对31例呼吸道感染患者研究了头孢西丁（CFX）的临床疗效。结果如下：就临床疗效而言，31例患者中，CFX疗效优者5例，良者13例，中者8例，差者5例；有效率为58.1%。支气管肺炎有效率为57.1%，肺炎为61.1%，慢性呼吸道感染急性加重为50.0%。每日4g及以下组有效率为70.6%，每日6g及以上组为42.9%。既往对其他抗生素无反应的6例患者中有效率为50.0%。至于副作用，仅1例患者出现皮疹。未观察到因CFX导致的实验室检查异常。总之，CFX是治疗呼吸道感染的一种有用药物。
